AKERO THERAPEUTICS INC (AKRO)

Upcoming Events

Oct 1, 2026, 4:00:00 AM UTC

Phase 3 Efruxifermin NASH/MASH Trial Completion Expected

Akero Therapeutics is conducting a Phase 3 clinical trial of Efruxifermin (EFX) in patients with non-invasively diagnosed nonalcoholic steatohepatitis (NASH/MASH) and nonalcoholic fatty liver disease (NAFLD/MASLD). The study, enrolling 700 participants, is expected to complete on October 1, 2026. Efruxifermin is an investigational FGF21 analog targeting metabolic liver diseases. The trial's primary objective is to assess safety and tolerability compared to placebo.

trial completion

Oct 1, 2029, 4:00:00 AM UTC

Expected Trial Completion for Efruxifermin Study in Compensated Cirrhosis Due to NASH/MASH

Akero Therapeutics is conducting a Phase 3, randomized, double-blind, placebo-controlled trial of efruxifermin (EFX) in 1,150 subjects with compensated cirrhosis due to NASH/MASH. The study is expected to complete on October 1, 2029. Efruxifermin is an investigational FGF21 analog targeting metabolic and fibrotic pathways in NASH/MASH, a progressive liver disease with limited treatment options.

trial completion

Nov 1, 2032, 4:00:00 AM UTC

Expected Completion of Efruxifermin Phase 3 Trial in NASH/MASH

Akero Therapeutics is conducting a Phase 3, randomized, double-blind, placebo-controlled trial of efruxifermin (EFX) in 1,650 subjects with non-cirrhotic NASH/MASH and fibrosis stages F2 or F3. The trial is expected to complete on November 1, 2032. Efruxifermin is an investigational FGF21 analog targeting metabolic liver diseases. The study's outcome will inform potential regulatory submissions for EFX in NASH/MASH.

trial completion